lifestyle.sourcefed.com

Author: Inspira Technologies

Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

February 17, 2026
Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

February 13, 2026
Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment

February 12, 2026
Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

February 11, 2026
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

February 11, 2026
ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center

January 29, 2026
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

January 21, 2026